The obesity market has become so competitive that companies no longer wait for their drugs to meet in the same clinical trial before declaring a winner. Eli Lilly said Monday that its oral GLP-1 drug Foundayo produced greater weight loss and better blood-sugar reductions than Novo Nordisk’s 25-milligram oral semaglutide in adults with type 2 diabetes.
It is a compelling headline. It is also an indirect comparison built from two different late-stage studies.
The Science Behind the Claim
According to Reuters, Lilly’s analysis estimated that 17.2 mg Foundayo produced roughly 1.5% to 2.4% more weight loss and reduced A1C by approximately 0.3 to 0.6 percentage points more than the higher-dose semaglutide pill.
The drugs never actually faced each other in the same randomized trial.
Those are not meaningless differences. In a market this large, a few percentage points can translate into prescribing preference, payer leverage and billions of dollars. But indirect comparisons depend on statistical adjustment to make separate study populations resemble one another. That is not the same thing as randomizing patients to Drug A or Drug B under one protocol.
Why the Methodology Matters
Lilly itself acknowledged that a head-to-head trial would be more definitive. Novo pushed back by noting that the analysis concerned people with type 2 diabetes, a population that generally loses less weight than people enrolled in obesity-only trials.
Both statements are true, which is exactly why this episode is worth watching. The science is becoming inseparable from the marketing war.
The Commercial Stakes Are Enormous
There is another wrinkle. Novo’s 25-mg oral semaglutide is not yet FDA-approved for diabetes at that dose, with a regulatory decision expected later in 2026.
So the public is being handed a competitive scoreboard involving one company’s newly approved oral product and another company’s still-pending higher-dose formulation, compared across separate trials.
That does not make the analysis useless. It makes the context mandatory.
Expect More Comparisons Like This
This is likely to become normal. As oral obesity drugs multiply, companies will produce network meta-analyses, matching-adjusted indirect comparisons and real-world database studies long before every interesting pair of drugs has been tested head-to-head.
Some will be rigorous. Some will be promotional. Most will be both science and strategy at the same time.
Grey Pepper’s Rule
Grey Pepper’s rule is simple: when a company says its drug is better, do not stop at the percentage. Ask who was studied, what dose was used, how long treatment lasted, whether the populations were comparable and — most importantly — whether the two drugs ever occupied the same randomized trial.
Because in the new obesity arms race, even the footnotes have competitors.
